Ikena Oncology Inc (IKNA) - Total Liabilities
Based on the latest financial reports, Ikena Oncology Inc (IKNA) has total liabilities worth $10.26 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ikena Oncology Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Ikena Oncology Inc's total liabilities have evolved over time, based on quarterly financial data. See Ikena Oncology Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Ikena Oncology Inc Competitors by Total Liabilities
The table below lists competitors of Ikena Oncology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
JKG Land Bhd
KLSE:6769
|
Malaysia | RM256.78 Million |
|
Lixte Biotechnology Holdings Inc
NASDAQ:LIXT
|
USA | $1.77 Million |
|
Pansar Bhd
KLSE:8419
|
Malaysia | RM447.76 Million |
|
TEAM INC. DL-30
F:T9CA
|
Germany | €509.93 Million |
|
Arovella Therapeutics Ltd
AU:ALA
|
Australia | AU$1.33 Million |
|
Korfez Gayrimenkul Yatirim
IS:KRGYO
|
Turkey | TL365.39 Million |
|
Cimbeton Hazirbeton ve Prefabrik Yapi Elemanlari Sanayi ve Ticaret AS
IS:CMBTN
|
Turkey | TL1.98 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Ikena Oncology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Ikena Oncology Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ikena Oncology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ikena Oncology Inc (2018–2024)
The table below shows the annual total liabilities of Ikena Oncology Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $15.58 Million | -30.26% |
| 2023-12-31 | $22.34 Million | -11.68% |
| 2022-12-31 | $25.29 Million | -36.78% |
| 2021-12-31 | $40.00 Million | -85.15% |
| 2020-12-31 | $269.45 Million | +82.76% |
| 2019-12-31 | $147.44 Million | +121.66% |
| 2018-12-31 | $66.52 Million | -- |
About Ikena Oncology Inc
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by… Read more